The importance of standardisation of laboratory evaluations in HIV vaccine trials.
It is important to evaluate HIV-1-specific immunological responses elicited by therapeutic or prophylactic vaccines using precise, standardised assays, so that the immunogenicity and putative efficacy of candidate vaccines may be compared. Different well-validated assays must be used to quantitate specific responses, to determine which particular strategies may be efficacious.
Gotch
Frances
F
Department of Immunology, Imperial College, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK. f.gotch@imperial.ac.uk
Holmes
Harvey
H
Imami
Nesrina
N
D016915:AIDS Vaccines / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay; D015483:HIV Antibodies / Q000032:analysis; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007159:Immunologic Tests / Q000592:standards*; D008213:Lymphocyte Activation; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D016915:AIDS Vaccines; D016207:Cytokines; D015483:HIV Antibodies